Sp1/Sp3 transcription factors regulate hallmarks of megakaryocyte maturation and platelet formation and function

Blood

Volumn 125, Issue 12, 2015, Pages 1957-1967

  Meinders, Marjolein ^a   Kulu, Divine I ^b   Van De Werken, Harmen J G ^b   Hoogenboezem, Mark ^a   Janssen, Hans ^c   Brouwer, Rutger W W ^b   Van Ijcken, Wilfred F J ^b   Rijkers, Erik Jan ^b   Demmers, Jeroen A A ^b   Krüger, Imme ^d   Van Den Berg, Timo K ^a   Suske, Guntram ^d   Gutiérrez, Laura ^a   Philipsen, Sjaak ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 IODO 1 NAPHTHALENESULFONYL)HEXAHYDRO 1H 1,4 DIAZEPINE; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB ALPHA; MYOSIN LIGHT CHAIN KINASE; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3; AZEPINE DERIVATIVE; CLEC-2 PROTEIN, MOUSE; LECTIN; NAPHTHALENE DERIVATIVE; PLATELET MEMBRANE GLYCOPROTEIN VI; PROTEOME; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW; CELL CULTURE; CELL MATURATION; ELECTRON MICROSCOPY; ERYTHROCYTE; FLOW CYTOMETRY; HEMATOPOIESIS; HEMATOPOIETIC SYSTEM; LEUKOCYTE; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; ANIMAL; CHEMISTRY; CYTOLOGY; GENETICS; KNOCKOUT MOUSE; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; AZEPINES; BLOOD PLATELETS; BONE MARROW; FLOW CYTOMETRY; LECTINS, C-TYPE; MEGAKARYOCYTES; MICE; MICE, KNOCKOUT; NAPHTHALENES; PLATELET AGGREGATION; PLATELET MEMBRANE GLYCOPROTEINS; PROTEOME; SIGNAL TRANSDUCTION; SP1 TRANSCRIPTION FACTOR; SP3 TRANSCRIPTION FACTOR; SPLEEN; THROMBOCYTOPENIA; TRANSCRIPTION FACTORS;

EID: 84925372722     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-08-593343     Document Type: Article

References (78)

1. Bluteau D, Lordier L, Di Stefano A, et al. Regulation of megakaryocyte maturation and platelet formation. J Thromb Haemost. 2009;7(Suppl 1):227-234.
2. Geddis AE. Megakaryopoiesis. Semin Hematol. 2010;47(3):212-219.
3. Italiano JE Jr. Unraveling mechanisms that control platelet production. Semin Thromb Hemost. 2013;39(1):15-24.
4. Schmitt A, Guichard J, Massé JM, Debili N, Cramer EM. Of mice and men: comparison of the ultrastructure of megakaryocytes and platelets. Exp Hematol. 2001;29(11):1295-1302.
5. Kuter DJ. The physiology of platelet production. Stem Cells. 1996;14(Suppl 1):88-101.
6. Junt T, Schulze H, Chen Z, et al. Dynamic visualization of thrombopoiesis within bone marrow. Science. 2007;317(5845):1767-1770.
7. Geddis AE. Inherited thrombocytopenias: an approach to diagnosis and management. Int J Lab Hematol. 2013;35(1):14-25.
8. Pecci A, Bozzi V, Panza E, et al. Mutations responsible for MYH9-related thrombocytopenia impair SDF-1-driven migration of megakaryoblastic cells. Thromb Haemost. 2011;106(4):693-704.
9. Cines DB, Bussel JB, McMillan RB, Zehnder JL. Congenital and acquired thrombocytopenia. Hematology (Am Soc Hematol Educ Program). 2004;390-406.
10. Kistangari G, McCrae KR. Immune thrombocytopenia. Hematol Oncol Clin North Am. 2013;27(3):495-520.
11. Schiødt FV, Balko J, Schilsky M, Harrison ME, Thornton A, Lee WM; Acute Liver Failure Study Group. Thrombopoietin in acute liver failure. Hepatology. 2003;37(3):558-561.
12. Balduini CL, Savoia A, Seri M. Inherited thrombocytopenias frequently diagnosed in adults. J Thromb Haemost. 2013;11(6):1006-1019.
13. Nurden P, Debili N, Coupry I, et al. Thrombocytopenia resulting from mutations in filamin A can be expressed as an isolated syndrome. Blood. 2011;118(22):5928-5937.
14. Nurden P, Nurden AT. Congenital disorders associated with platelet dysfunctions. Thromb Haemost. 2008;99(2):253-263.
15. Tijssen MR, Ghevaert C. Transcription factors in late megakaryopoiesis and related platelet disorders. J Thromb Haemost. 2013;11(4):593-604.
16. Gutiérrez L, Tsukamoto S, Suzuki M, et al. Ablation of Gata1 in adult mice results in aplastic crisis, revealing its essential role in steady-state and stress erythropoiesis. Blood. 2008;111(8):4375-4385.
17. Vyas P, Ault K, Jackson CW, Orkin SH, Shivdasani RA. Consequences of GATA-1 deficiency in megakaryocytes and platelets. Blood. 1999;93(9):2867-2875.
18. Freson K, Matthijs G, Thys C, et al. Different substitutions at residue D218 of the X-linked transcription factor GATA1 lead to altered clinical severity of macrothrombocytopenia and anemia and are associated with variable skewed X inactivation. Hum Mol Genet. 2002;11(2):147-152.
19. Shimizu R, Engel JD, Yamamoto M. GATA1-related leukaemias. Nat Rev Cancer. 2008;8(4):279-287.
20. Stevenson WS, Morel-Kopp MC, Chen Q, et al. GFI1B mutation causes a bleeding disorder with abnormal platelet function. J Thromb Haemost. 2013;11(11):2039-2047.
21. Ichikawa M, Yoshimi A, Nakagawa M, Nishimoto N, Watanabe-Okochi N, Kurokawa M. A role for RUNX1 in hematopoiesis and myeloid leukemia. Int J Hematol. 2013;97(6):726-734.
22. Fujita R, Takayama-Tsujimoto M, Satoh H, et al. NF-E2 p45 is important for establishing normal function of platelets. Mol Cell Biol. 2013;33(14):2659-2670.
23. McCormack MP, Hall MA, Schoenwaelder SM, et al. A critical role for the transcription factor Scl in platelet production during stress thrombopoiesis. Blood. 2006;108(7):2248-2256.
24. Stockley J, Morgan NV, Bem D, et al UK Genotyping and Phenotyping of Platelets Study Group. Enrichment of FLI1 and RUNX1 mutations in families with excessive bleeding and platelet dense granule secretion defects. Blood. 2013;122(25):4090-4093.
25. Suske G, Bruford E, Philipsen S. Mammalian SP/KLF transcription factors: bring in the family. Genomics. 2005;85(5):551-556.
26. Göllner H, Bouwman P, Mangold M, et al. Complex phenotype of mice homozygous for a null mutation in the Sp4 transcription factor gene. Genes Cells. 2001;6(8):689-697.
27. Marin M, Karis A, Visser P, Grosveld F, Philipsen S. Transcription factor Sp1 is essential for early embryonic development but dispensable for cell growth and differentiation. Cell. 1997;89(4):619-628.
28. Bouwman P, Göllner H, Elsässer HP, et al. Transcription factor Sp3 is essential for post-natal survival and late tooth development. EMBO J. 2000;19(4):655-661.
29. Van Loo PF, Bouwman P, Ling KW, et al. Impaired hematopoiesis in mice lacking the transcription factor Sp3. Blood. 2003;102(3):858-866.
30. van Loo PF, Mahtab EA, Wisse LJ, et al. Transcription factor Sp3 knockout mice display serious cardiac malformations. Mol Cell Biol. 2007;27(24):8571-8582.
31. Krüger I, Vollmer M, Simmons DG, Elsässer HP, Philipsen S, Suske G. Sp1/Sp3 compound heterozygous mice are not viable: impaired erythropoiesis and severe placental defects. Dev Dyn. 2007;236(8):2235-2244.
32. Kühn R, Schwenk F, Aguet M, Rajewsky K. Inducible gene targeting in mice. Science. 1995;269(5229):1427-1429.
33. Tiedt R, Schomber T, Hao-Shen H, Skoda RC. Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo. Blood. 2007;109(4):1503-1506.
34. De Cuyper IM, Meinders M, van de Vijver E, et al. A novel flow cytometry-based platelet aggregation assay. Blood. 2013;121(10):e70-e80.
35. Shimizu R, Ohneda K, Engel JD, Trainor CD, Yamamoto M. Transgenic rescue of GATA-1-deficient mice with GATA-1 lacking a FOG-1 association site phenocopies patients with X-linked thrombocytopenia. Blood. 2004;103(7):2560-2567.
36. Eckly A, Strassel C, Cazenave JP, Lanza F, Léon C, Gachet C. Characterization of megakaryocyte development in the native bone marrow environment. Methods Mol Biol. 2012;788:175-192.
37. Lichtman MA, Chamberlain JK, Simon W, Santillo PA. Parasinusoidal location of megakaryocytes in marrow: a determinant of platelet release. Am J Hematol. 1978;4(4):303-312.
38. Pitchford SC, Lodie T, Rankin SM. VEGFR1 stimulates a CXCR4-dependent translocation of megakaryocytes to the vascular niche, enhancing platelet production in mice. Blood. 2012;120(14):2787-2795.
39. Tavassoli M, Aoki M. Localization of megakaryocytes in the bone marrow. Blood Cells. 1989;15(1):3-14.
40. Rivera J, Lozano ML, Navarro-Núñez L, Vicente V. Platelet receptors and signaling in the dynamics of thrombus formation. Haematologica. 2009;94(5):700-711.
41. Eckly A, Rinckel JY, Laeuffer P, et al. Proplatelet formation deficit and megakaryocyte death contribute to thrombocytopenia in Myh9 knockout mice. J Thromb Haemost. 2010;8(10):2243-2251.
42. Ozaki Y, Suzuki-Inoue K, Inoue O. Platelet receptors activated via mulitmerization: glycoprotein VI, GPIb-IX-V, and CLEC-2. J Thromb Haemost. 2013;11(suppl 1):330-339.
43. Falet H, Pollitt AY, Begonja AJ, et al. A novel interaction between FlnA and Syk regulates platelet ITAM-mediated receptor signaling and function. J Exp Med. 2010;207(9):1967-1979.
44. Stefanini L, Bergmeier W. CalDAG-GEFI and platelet activation. Platelets. 2010;21(4):239-243.
45. Kuijpers TW, van de Vijver E, Weterman MA, et al. LAD-1/variant syndrome is caused by mutations in FERMT3. Blood. 2009;113(19):4740-4746.
46. Yin F, Hoggatt AM, Zhou J, Herring BP. 130-kDa smooth muscle myosin light chain kinase is transcribed from a CArG-dependent, internal promoter within the mouse mylk gene. Am J Physiol Cell Physiol. 2006;290(6):C1599-C1609.
47. Dabrowska R, Hartshorne DJA. A Ca2+-and modulator-dependent myosin light chain kinase from non-muscle cells. Biochem Biophys Res Commun. 1978;85(4):1352-1359.
48. Hathaway DR, Adelstein RS. Human platelet myosin light chain kinase requires the calcium-binding protein calmodulin for activity. Proc Natl Acad Sci USA. 1979;76(4):1653-1657.
49. Hathaway DR, Eaton CR, Adelstein RS. Regulation of human platelet myosin light chain kinase by the catalytic subunit of cyclic AMP-dependent protein kinase. Nature. 1981;291(5812):252-256.
50. Saitoh M, Naka M, Hidaka H. The modulatory role of myosin light chain phosphorylation in human platelet activation. Biochem Biophys Res Commun. 1986;140(1):280-287.
51. Tournoij E, Weber GJ, Akkerman JW, et al. Mlck1a is expressed in zebrafish thrombocytes and is an essential component of thrombus formation. J Thromb Haemost. 2010;8(3):588-595.
52. Makishima M, Honma Y, Hozumi M, Sampi K, Hattori M, Motoyoshi K. Induction of differentiation of human leukemia cells by inhibitors of myosin light chain kinase. FEBS Lett. 1991;287(1-2):175-177.
53. Watson SP, Herbert JM, Pollitt AY. GPVI and CLEC-2 in hemostasis and vascular integrity. J Thromb Haemost. 2010;8(7):1456-1467.
54. Kennedy BJ. Metabolic and toxic effects of mithramycin during tumor therapy. Am J Med. 1970;49(4):494-503.
55. Yamreudeewong W, Henann NE, Fazio A, Rangaraj U. Possible severe thrombocytopenia associated with a single dose of plicamycin. Ann Pharmacother. 1992;26(11):1369-1373.
56. Sanda N, Fujimori Y, Kashiwagi T, et al. An Sp1 binding site mutation of the PROS1 promoter in a patient with protein S deficiency. Br J Haematol. 2007;138(5):663-665.
57. Wang W, Huang L, Ma Q, et al. Homozygous intronic mutation leading to inefficient transcription combined with a novel frameshift mutation in F13A1 gene causes FXIII deficiency. J Hum Genet. 2011;56(6):460-463.
58. Kaur G, Jalagadugula G, Mao G, Rao AK. RUNX1/core binding factor A2 regulates platelet 12-lipoxygenase gene (ALOX12): studies in human RUNX1 haplodeficiency. Blood. 2010;115(15):3128-3135.
59. Sun L, Gorospe JR, Hoffman EP, Rao AK. Decreased platelet expression of myosin regulatory light chain polypeptide (MYL9) and other genes with platelet dysfunction and CBFA2/RUNX1 mutation: insights from platelet expression profiling. J Thromb Haemost. 2007;5(1):146-154.
60. Nurden A, Nurden P. Advances in our understanding of the molecular basis of disorders of platelet function. J Thromb Haemost. 2011;9(suppl 1):76-91.
61. Léon C, Eckly A, Hechler B, et al. Megakaryocyte-restricted MYH9 inactivation dramatically affects hemostasis while preserving platelet aggregation and secretion. Blood. 2007;110(9):3183-3191.
62. D'Addario M, Arora PD, Ellen RP, McCulloch CA. Interaction of p38 and Sp1 in a mechanical force-induced, beta 1 integrin-mediated transcriptional circuit that regulates the actin-binding protein filamin-A. J Biol Chem. 2002;277(49):47541-47550.
63. Jurak Begonja A, Hoffmeister KM, Hartwig JH, Falet H. FlnA-null megakaryocytes prematurely release large and fragile platelets that circulate poorly. Blood. 2011;118(8):2285-2295.
64. Falati S, Edmead CE, Poole AW. Glycoprotein Ib-V-IX, a receptor for von Willebrand factor, couples physically and functionally to the Fc receptor gamma-chain, Fyn, and Lyn to activate human platelets. Blood. 1999;94(5):1648-1656.
65. Liu J, Pestina TI, Berndt MC, Jackson CW, Gartner TK. Botrocetin/VWF-induced signaling through GPIb-IX-V produces TxA2 in an alphaIIbbeta3- and aggregation-independent manner. Blood. 2005;106(8):2750-2756.
66. Riondino S, Gazzaniga PP, Pulcinelli FM. Convulxin induces platelet shape change through myosin light chain kinase and Rho kinase. Eur J Biochem. 2002;269(23):5878-5884.
67. Toth-Zsamboki E, Oury C, Cornelissen H, De Vos R, Vermylen J, Hoylaerts MF. P2X1-mediated ERK2 activation amplifies the collagen-induced platelet secretion by enhancing myosin light chain kinase activation. J Biol Chem. 2003;278(47):46661-46667.
68. Di Buduo CA, Moccia F, Battiston M, et al. The importance of calcium in the regulation of megakaryocyte function. Haematologica. 2014;99(4):769-778.
69. Larson MK, Watson SP. A product of their environment: do megakaryocytes rely on extracellular cues for proplatelet formation? Platelets. 2006;17(7):435-440.
70. Larson MK, Watson SP. Regulation of proplatelet formation and platelet release by integrin alpha IIb beta3. Blood. 2006;108(5):1509-1514.
71. Chang Y, Auradé F, Larbret F, et al. Proplatelet formation is regulated by the Rho/ROCK pathway. Blood. 2007;109(10):4229-4236.
72. Xu J, Gao XP, Ramchandran R, Zhao YY, Vogel SM, Malik AB. Nonmuscle myosin light-chain kinase mediates neutrophil transmigration in sepsis-induced lung inflammation by activating beta2 integrins. Nat Immunol. 2008;9(8):880-886.
73. Ikebe M, Reardon S, Fay FS. Primary structure required for the inhibition of smooth muscle myosin light chain kinase. FEBS Lett. 1992;312(2-3):245-248.
74. Rojnuckarin P, Kaushansky K. Actin reorganization and proplatelet formation in murine megakaryocytes: the role of protein kinase calpha. Blood. 2001;97(1):154-161.
75. Tamaru S, Kitajima K, Nakano T, et al. Calyculin A retraction of mature megakaryocytes proplatelets from embryonic stem cells. Biochem Biophys Res Commun. 2008;366(3):763-768.
76. Patel SR, Richardson JL, Schulze H, et al. Differential roles of microtubule assembly and sliding in proplatelet formation by megakaryocytes. Blood. 2005;106(13):4076-4085.
77. Radley JM, Haller CJ. The demarcation membrane system of the megakaryocyte: a misnomer? Blood. 1982;60(1):213-219.
78. Yvon AM, Gross DJ, Wadsworth P. Antagonistic forces generated by myosin II and cytoplasmic dynein regulate microtubule turnover, movement, and organization in interphase cells. Proc Natl Acad Sci USA. 2001;98(15):8656-8661.